Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk AS    NOVO B   DK0060534915


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novo Nordisk : Trial shows cardiovascular safety with Novo Nordisks diabetes drug

share with twitter share with LinkedIn share with facebook
share via e-mail
06/13/2019 | 06:36am EDT

Novo Nordisk has reported that its oral semaglutide medicine showed non-inferiority compared to placebo in major adverse cardiovascular events (MACE) during the PIONEER 6 clinical trial in type 2 diabetes patients.

The trials primary endpoint was the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke.

PIONEER 6 met the endpoint with a hazard ratio of 0.79 in favour of semaglutide compared to placebo.

The data is an aggregation of 137 first major adverse cardiovascular events and a median follow-up of 16 months.

Oral semaglutide is an investigational glucagon-like peptide-1 (GLP-1) analogue formulated as a pill.

The randomised, double-blinded, placebo-controlled, event-driven, pre-approval cardiovascular outcomes trial compared the cardiovascular safety of the therapeutic to placebo when added to standard of care. It recruited a total of 3,183 patients at high risk of cardiovascular events.

According to the findings, the MACE was driven by its individual components.

Cardiovascular death events were 15 with oral semaglutide compared to 30 with placebo, while non-fatal stroke events were 12 versus 16.

However, the number of non-fatal myocardial infarctions with the therapeutic was not significantly different to placebo, with the numbers being recorded at 37 and 31, respectively.

In addition, the oral semaglutide group showed significantly lower all-cause deaths compared to patients on placebo.

During the trial, the safety profile of Novo Nordisks drug was consistent with that of the GLP-1 receptor agonist class and similar to subcutaneous semaglutide.

Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard Thomsen said: The results of PIONEER 6 further strengthen the overall clinical evidence for oral semaglutide, building upon the strong clinical data reported throughout the PIONEER clinical trial programme.

We are excited about the potential of oral semaglutide to become the first and only oral GLP-1 treatment for people with type 2 diabetes.

The PIONEER clinical development programme involved 9,543 type 2 diabetes patients in ten trials.

(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVO NORDISK AS
08:26aNOVO NORDISK : A/S – Share repurchase programme
08:26aNOVO NORDISK : Disclosure of transaction data
10/09NOVO NORDISK : K-P CM inaugurates mobile diabetic clinic
10/08NOVO NORDISK : MIT - New capsule can orally deliver drugs that usually have to b..
10/07NOVO NORDISK : Disclosure of transaction data
10/07NOVO NORDISK A/S : – Share repurchase programme
10/04UNIVERSITY OF BIRMINGHAM : New partnership aims to identify new disease mechanis..
10/04EUROPE MARKETS: Defensive Plays Nudge European Stocks Higher As Key Jobs Data..
10/02NOVO NORDISK : and Noom to partner around digital health solutions to help peopl..
09/30NOVO NORDISK : A/S – Share repurchase programme
More news
Financials (DKK)
Sales 2019 121 B
EBIT 2019 52 731 M
Net income 2019 39 094 M
Finance 2019 11 374 M
Yield 2019 2,43%
P/E ratio 2019 21,1x
P/E ratio 2020 18,3x
EV / Sales2019 6,70x
EV / Sales2020 6,27x
Capitalization 821 B
Duration : Period :
Novo Nordisk AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK AS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 367,82  DKK
Last Close Price 347,15  DKK
Spread / Highest target 29,6%
Spread / Average Target 5,95%
Spread / Lowest Target -35,8%
EPS Revisions
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK AS17.25%121 422
JOHNSON & JOHNSON0.01%346 602
ROCHE HOLDING AG18.02%248 022
MERCK AND COMPANY10.38%215 942
PFIZER-17.27%199 726
NOVARTIS14.95%199 287